Protalix BioTherapeutics, Inc. - PLX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 30, 2026 | SCHEDULE 13G/A | MAK Capital Fund LP | 4.5% | 3,616,289 | View |
| Mar 30, 2026 | SCHEDULE 13G/A | MAK CAPITAL ONE LLC | 4.5% | 3,616,289 | View |
| Mar 30, 2026 | SCHEDULE 13G/A | Kaufman Michael A | 4.5% | 3,616,289 | View |
| Mar 04, 2026 | SCHEDULE 13G | MAK Capital Fund LP | 5.8% | 4,649,599 | View |
| Mar 04, 2026 | SCHEDULE 13G | MAK CAPITAL ONE LLC | 5.8% | 4,649,599 | View |
| Mar 04, 2026 | SCHEDULE 13G | Kaufman Michael A | 5.8% | 4,649,599 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.